Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Diabetes and Periodontal Therapy Trial
A Multicenter Randomized Single-Masked Clinical Trial Testing the Effect of Non-surgical Periodontal Therapy on Glycosylated Hemoglobin (HbA1c) Levels in Subjects With Type 2 Diabetes and Chronic Periodontitis
Status: Archived
Stony Brook University Hospital and Medical Center
mi
from
Stony Brook, NY
Diabetes and Periodontal Therapy Trial
A Multicenter Randomized Single-Masked Clinical Trial Testing the Effect of Non-surgical Periodontal Therapy on Glycosylated Hemoglobin (HbA1c) Levels in Subjects With Type 2 Diabetes and Chronic Periodontitis
Status: Archived
Updated: 1/1/1970
Stony Brook University Hospital and Medical Center
mi
from
Stony Brook, NY
Diabetes and Periodontal Therapy Trial
A Multicenter Randomized Single-Masked Clinical Trial Testing the Effect of Non-surgical Periodontal Therapy on Glycosylated Hemoglobin (HbA1c) Levels in Subjects With Type 2 Diabetes and Chronic Periodontitis
Status: Archived
Clinical Site: University of Texas Health Science Center
mi
from
San Antonio, TX
Diabetes and Periodontal Therapy Trial
A Multicenter Randomized Single-Masked Clinical Trial Testing the Effect of Non-surgical Periodontal Therapy on Glycosylated Hemoglobin (HbA1c) Levels in Subjects With Type 2 Diabetes and Chronic Periodontitis
Status: Archived
Updated: 1/1/1970
Clinical Site: University of Texas Health Science Center
mi
from
San Antonio, TX
Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes
Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) to Improve Insulin Secretion and Action in Subjects With Type 2 Diabetes
Status: Archived
The University of Texas Health Science Center at San Antonio, Medical Arts and Research Center
mi
from
San Antonio, TX
Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes
Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) to Improve Insulin Secretion and Action in Subjects With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
The University of Texas Health Science Center at San Antonio, Medical Arts and Research Center
mi
from
San Antonio, TX
Gestational Diabetes Follow Up Study
Es Mejor Saber: A Proactive Approach to Gestational Diabetes Follow Up
Status: Archived
Los Angeles County-USC Medical Center
mi
from
Los Angeles, CA
Gestational Diabetes Follow Up Study
Es Mejor Saber: A Proactive Approach to Gestational Diabetes Follow Up
Status: Archived
Updated: 1/1/1970
Los Angeles County-USC Medical Center
mi
from
Los Angeles, CA
Effectiveness Study of Community-Based, Peer-Led Education on Weight Loss and Diabetes
Collaborations for Health Improvement in East Harlem—Project HEED
Status: Archived
Mount Sinai Hospital
mi
from
New York, NY
Effectiveness Study of Community-Based, Peer-Led Education on Weight Loss and Diabetes
Collaborations for Health Improvement in East Harlem—Project HEED
Status: Archived
Updated: 1/1/1970
Mount Sinai Hospital
mi
from
New York, NY
Prevalence of Vitamin D Deficiency in Type 1 Diabetes Mellitus and Effect on Insulin Requirements After Supplementation With Vitamin D
Prevalence of Vitamin D Deficiency in Type 1 Diabetes Mellitus and Effect on Insulin Requirements After Supplementation With Vitamin D-A Pilot Study
Status: Archived
Wiiliam Beaumont Hospital
mi
from
Royal oak, MI
Prevalence of Vitamin D Deficiency in Type 1 Diabetes Mellitus and Effect on Insulin Requirements After Supplementation With Vitamin D
Prevalence of Vitamin D Deficiency in Type 1 Diabetes Mellitus and Effect on Insulin Requirements After Supplementation With Vitamin D-A Pilot Study
Status: Archived
Updated: 1/1/1970
Wiiliam Beaumont Hospital
mi
from
Royal oak, MI
Genetic Counseling and Lifestyle Change for Diabetes Prevention
Genetic Counseling and Lifestyle Change for Diabetes Prevention
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Genetic Counseling and Lifestyle Change for Diabetes Prevention
Genetic Counseling and Lifestyle Change for Diabetes Prevention
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Peer Coaching for Low-Income Patients With Diabetes in Primary Care
Peer Coaching for Low-Income Patients With Diabetes in Primary Care
Status: Archived
San Francisco General Hospital
mi
from
San Francisco, CA
Peer Coaching for Low-Income Patients With Diabetes in Primary Care
Peer Coaching for Low-Income Patients With Diabetes in Primary Care
Status: Archived
Updated: 1/1/1970
San Francisco General Hospital
mi
from
San Francisco, CA
Does Pioglitazone Increase the Production of Prostacyclin (PGI2) and/or 15-EPI-Lipoxin A4 in Humans With Diabetes Mellitus Type 2?
Does Pioglitazone Increase the Production of Prostacyclin (PGI2) and/or 15-EPI-Lipoxin A4 in Humans With Diabetes Mellitus Type 2?
Status: Archived
Baylor School of Medicine
mi
from
Houston, TX
Does Pioglitazone Increase the Production of Prostacyclin (PGI2) and/or 15-EPI-Lipoxin A4 in Humans With Diabetes Mellitus Type 2?
Does Pioglitazone Increase the Production of Prostacyclin (PGI2) and/or 15-EPI-Lipoxin A4 in Humans With Diabetes Mellitus Type 2?
Status: Archived
Updated: 1/1/1970
Baylor School of Medicine
mi
from
Houston, TX
A Very High Fiber Diet Versus a Low-carbohydrate Diet for Weight Loss
A Very High Fiber Diet Versus a Low-carbohydrate Diet for Weight Loss in Obese Individuals With or Without Type 2 Diabetes
Status: Archived
Loma Linda Medical Center
mi
from
Loma Linda, CA
A Very High Fiber Diet Versus a Low-carbohydrate Diet for Weight Loss
A Very High Fiber Diet Versus a Low-carbohydrate Diet for Weight Loss in Obese Individuals With or Without Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Loma Linda Medical Center
mi
from
Loma Linda, CA
Study Of Safety And Efficacy Of PF-04971729 In Patients With Type 2 Diabetes
Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Archived
Raleigh Regional Cancer Center
mi
from
Beckley, WV
Study Of Safety And Efficacy Of PF-04971729 In Patients With Type 2 Diabetes
Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Archived
Updated: 1/1/1970
Raleigh Regional Cancer Center
mi
from
Beckley, WV
Study Of Safety And Efficacy Of PF-04971729 In Patients With Type 2 Diabetes
Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Archived
Pfizer Investigational Site
mi
from
Atlanta, GA
Study Of Safety And Efficacy Of PF-04971729 In Patients With Type 2 Diabetes
Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Atlanta, GA
Study Of Safety And Efficacy Of PF-04971729 In Patients With Type 2 Diabetes
Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Archived
Pfizer Investigational Site
mi
from
Honolulu, HI
Study Of Safety And Efficacy Of PF-04971729 In Patients With Type 2 Diabetes
Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Honolulu, HI
Study Of Safety And Efficacy Of PF-04971729 In Patients With Type 2 Diabetes
Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Archived
Pfizer Investigational Site
mi
from
Ashland, KY
Study Of Safety And Efficacy Of PF-04971729 In Patients With Type 2 Diabetes
Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Ashland, KY
Study Of Safety And Efficacy Of PF-04971729 In Patients With Type 2 Diabetes
Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Archived
Pfizer Investigational Site
mi
from
Incline Village, NV
Study Of Safety And Efficacy Of PF-04971729 In Patients With Type 2 Diabetes
Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Incline Village, NV
Study Of Safety And Efficacy Of PF-04971729 In Patients With Type 2 Diabetes
Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Archived
Pfizer Investigational Site
mi
from
Clifton, NJ
Study Of Safety And Efficacy Of PF-04971729 In Patients With Type 2 Diabetes
Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Clifton, NJ
Study Of Safety And Efficacy Of PF-04971729 In Patients With Type 2 Diabetes
Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Archived
Fletcher Allen Health Care
mi
from
Burlington, VT
Study Of Safety And Efficacy Of PF-04971729 In Patients With Type 2 Diabetes
Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Archived
Updated: 1/1/1970
Fletcher Allen Health Care
mi
from
Burlington, VT
Study Of Safety And Efficacy Of PF-04971729 In Patients With Type 2 Diabetes
Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Archived
Pfizer Investigational Site
mi
from
Houston, TX
Study Of Safety And Efficacy Of PF-04971729 In Patients With Type 2 Diabetes
Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Houston, TX
Study Of Safety And Efficacy Of PF-04971729 In Patients With Type 2 Diabetes
Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Archived
Pfizer Investigational Site
mi
from
Burke, VA
Study Of Safety And Efficacy Of PF-04971729 In Patients With Type 2 Diabetes
Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Burke, VA
Study Of Safety And Efficacy Of PF-04971729 In Patients With Type 2 Diabetes
Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Archived
Pfizer Investigational Site
mi
from
Seattle, WA
Study Of Safety And Efficacy Of PF-04971729 In Patients With Type 2 Diabetes
Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Seattle, WA
Study Of Safety And Efficacy Of PF-04971729 In Patients With Type 2 Diabetes
Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Archived
Pfizer Investigational Site
mi
from
Madison, WI
Study Of Safety And Efficacy Of PF-04971729 In Patients With Type 2 Diabetes
Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Madison, WI
The Effects of Nebivolol on Aortic Impedance Parameters in Type 2 Diabetes (The Effort Trial)
The Effects of Nebivolol on Aortic Impedance Parameters in Type 2 Diabetes
Status: Archived
University of Chicago
mi
from
Chicago, IL
The Effects of Nebivolol on Aortic Impedance Parameters in Type 2 Diabetes (The Effort Trial)
The Effects of Nebivolol on Aortic Impedance Parameters in Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
University of Chicago
mi
from
Chicago, IL
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Denver, CO
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Denver, CO
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Celebration, FL
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Celebration, FL
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Atlanta, GA
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Atlanta, GA
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Coeur D'Alene, ID
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Coeur D'Alene, ID
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Metairie, LA
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Metairie, LA
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Jackson, MS
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Jackson, MS
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
St Louis, MO
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
St Louis, MO
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Henderson, NV
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Henderson, NV
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Albuquerque, NM
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albuquerque, NM
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Charlotte, NC
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charlotte, NC
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Lima, OH
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lima, OH
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Ponca City, OK
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Ponca City, OK
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Philadelphia, PA
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Philadelphia, PA
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Charleston, SC
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charleston, SC
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Ogden, UT
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Ogden, UT
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Richmond, VA
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Richmond, VA
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Clinical Research Facility
mi
from
Scottsdale, AZ
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Scottsdale, AZ
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Dana-Farber / Harvard Cancer Center
mi
from
Boston, MA
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Updated: 1/1/1970
Dana-Farber / Harvard Cancer Center
mi
from
Boston, MA
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Clinical Research Facility
mi
from
Hartford, CT
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Hartford, CT
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Clinical Research Facility
mi
from
Miami, FL
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Miami, FL
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Aurora Memorial Hospital of Burlington
mi
from
Burlington, WI
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Updated: 1/1/1970
Aurora Memorial Hospital of Burlington
mi
from
Burlington, WI
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Updated: 1/1/1970
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Clinical Research Facility
mi
from
Idaho Falls, ID
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Idaho Falls, ID
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Maine Center for Cancer Medicine and Blood Disorders - Scarborough
mi
from
Scarborough, ME
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Updated: 1/1/1970
Maine Center for Cancer Medicine and Blood Disorders - Scarborough
mi
from
Scarborough, ME
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
University of Vermont College of Medicine
mi
from
Burlington, VT
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Updated: 1/1/1970
University of Vermont College of Medicine
mi
from
Burlington, VT
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Clinical Research Facility
mi
from
Topeka, KA
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Topeka, KA
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Clinical Research Facility
mi
from
Hazard, KY
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Hazard, KY